Kura Oncology KURA Stock
Kura Oncology Price Chart
Kura Oncology KURA Financial and Trading Overview
| Kura Oncology stock price | 10.62 USD |
| Previous Close | 10.65 USD |
| Open | 10.85 USD |
| Bid | 7.92 USD x 200 |
| Ask | 13.79 USD x 200 |
| Day's Range | 10.6 - 10.97 USD |
| 52 Week Range | 7.36 - 13.9 USD |
| Volume | 1.89M USD |
| Avg. Volume | 1.82M USD |
| Market Cap | 947.43M USD |
| Beta (5Y Monthly) | 0.434 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.37 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.85 USD |
KURA Valuation Measures
| Enterprise Value | 452.86M USD |
| Trailing P/E | N/A |
| Forward P/E | -4.6371484 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 12.268443 |
| Price/Book (mrq) | 19.577204 |
| Enterprise Value/Revenue | 5.864 |
| Enterprise Value/EBITDA | -1.429 |
Trading Information
Kura Oncology Stock Price History
| Beta (5Y Monthly) | 0.434 |
| 52-Week Change | 8.67% |
| S&P500 52-Week Change | 14.15% |
| 52 Week High | 13.9 USD |
| 52 Week Low | 7.36 USD |
| 50-Day Moving Average | 11.17 USD |
| 200-Day Moving Average | 9.81 USD |
KURA Share Statistics
| Avg. Volume (3 month) | 1.82M USD |
| Avg. Daily Volume (10-Days) | 1.97M USD |
| Shares Outstanding | 88.96M |
| Float | 70.43M |
| Short Ratio | 6.42 |
| % Held by Insiders | 1.39% |
| % Held by Institutions | 99.98% |
| Shares Short | 14.82M |
| Short % of Float | 17.10% |
| Short % of Shares Outstanding | 16.66% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -349.76% |
| Gross Margin | -236.71% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -31.30% |
| Return on Equity (ttm) | -167.70% |
Income Statement
| Revenue (ttm) | 77.23M USD |
| Revenue Per Share (ttm) | 0.88 USD |
| Quarterly Revenue Growth (yoy) | 36.50% |
| Gross Profit (ttm) | -182807008 USD |
| EBITDA | -316799008 USD |
| Net Income Avi to Common (ttm) | -296775008 USD |
| Diluted EPS (ttm) | -3.32 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 519.02M USD |
| Total Cash Per Share (mrq) | 5.83 USD |
| Total Debt (mrq) | 24.46M USD |
| Total Debt/Equity (mrq) | 50.5 USD |
| Current Ratio (mrq) | 4.733 |
| Book Value Per Share (mrq) | 0.544 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -111757000 USD |
| Levered Free Cash Flow (ttm) | -165880752 USD |
Profile of Kura Oncology
| Country | United States |
| State | CA |
| City | San Diego |
| Address | 4930 Directors Place |
| ZIP | 92121 |
| Phone | 858 500 8800 |
| Website | https://kuraoncology.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 260 |
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Q&A For Kura Oncology Stock
What is a current KURA stock price?
Kura Oncology KURA stock price today per share is 10.62 USD.
How to purchase Kura Oncology stock?
You can buy KURA shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Kura Oncology?
The stock symbol or ticker of Kura Oncology is KURA.
Which industry does the Kura Oncology company belong to?
The Kura Oncology industry is Biotechnology.
How many shares does Kura Oncology have in circulation?
The max supply of Kura Oncology shares is 88.96M.
What is Kura Oncology Price to Earnings Ratio (PE Ratio)?
Kura Oncology PE Ratio is now.
What was Kura Oncology earnings per share over the trailing 12 months (TTM)?
Kura Oncology EPS is -3.37 USD over the trailing 12 months.
Which sector does the Kura Oncology company belong to?
The Kura Oncology sector is Healthcare.
Kura Oncology KURA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
27477.31 USD — |
+1.05
|
7.04B USD — | 27223.49 USD — | 27544.06 USD — | — - | 7.04B USD — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
13524.02 USD — |
+1.07
|
— — | 13397.04 USD — | 13557.29 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
7022.12 USD — |
+1.07
|
— — | 6892.36 USD — | 7043.1 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1320 USD — |
+1.33
|
— — | 1298.21 USD — | 1322.56 USD — | — - | — — |
- {{ link.label }} {{link}}
